Timothy Jon Luker

USPTO Granted Patents = 21 (Patent Applications = 5)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 4.1

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

Leicestershire, GB (2010 - 2014)
Loughborough, GB (2003 - 2015)

Company Filing History:

Astra Zeneca U.k. Limited

patents

Years Active: 2003-2015

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8969350 - Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient (2015-03-03),

2. 8889692 - Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses (2014-11-18),

3. 8722741 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease (2014-05-13),

4. 8524715 - Phenoxyacetic acid derivatives useful for treating respiratory diseases (2013-09-03),

5. 8507544 - Bi-aryl amide compounds as CRTh2 receptor modulators (2013-08-13),

6. 8415394 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease (2013-04-09),

7. 8349897 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease (2013-01-08),

8. 8299246 - N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses (2012-10-30),

9. 8163905 - Compounds and their uses 708 (2012-04-24),

10. 8163727 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease (2012-04-24),

11. 8158820 - Compounds (2012-04-17),

12. 8148572 - Compounds (2012-04-03),

13. 8022248 - Substituted acids for the treatment of respiratory diseases (2011-09-20),

14. 8012980 - Isoquinolinone derivatives (2011-09-06),

15. 8008350 - Biphenyloxyacetic acid derivatives for the treatment of respiratory disease (2011-08-30),

Title: Timothy Jon Luker: A Pioneer in Pharmaceutical Innovations

Introduction

Timothy Jon Luker, a distinguished inventor based in Loughborough, GB, has made significant contributions to the pharmaceutical industry with a remarkable portfolio of 21 patents. His innovative work focuses on the development of novel compounds aimed at treating various medical conditions, particularly respiratory diseases.

Latest Patents

Among his latest inventions is a pharmaceutical product that comprises a p38 kinase inhibitor combined with a second active ingredient. This groundbreaking invention includes a first active component, N-Cyclopropyl-3-fluoro-4-methyl-5[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxo-1(2H)-pyrazinyl]-benzamide, and a selection of second active ingredients such as glucocorticoid receptor agonists, antioxidants, and various other compounds with therapeutic potential for treating respiratory diseases. Another prominent patent involves pyrazinone derivatives, their preparation processes, pharmaceutical compositions, and therapeutic applications, showcasing his expertise in medicinal chemistry.

Career Highlights

Luker's professional journey includes significant stints at reputable companies like AstraZeneca AB and AstraZeneca U.K. Limited. His work at these organizations has positioned him at the forefront of pharmaceutical innovation, where he has contributed to the development of essential therapeutic products.

Collaborations

Throughout his career, Timothy Jon Luker has collaborated with esteemed colleagues such as Stephen Thom and Rukhsana Tasneem Mohammed. These partnerships have fostered a collaborative environment that has led to the successful advancement of various pharmaceutical projects.

Conclusion

Timothy Jon Luker stands out as a highly influential figure in the realm of pharmaceutical innovations. With his extensive patent portfolio and collaborations with industry leaders, Luker's contributions continue to have a profound impact on the development of new therapeutic approaches. His dedication to advancing medical science through innovation underscores the essential role that inventors play in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.